User fee refund guidance
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers will receive a check within 30 days after FDA decides a user fee refund is warranted, according to a 1CBER/CDRH guidance dated Nov. 17 and posted Nov. 24. The document, entitled "Resolution of Disputes Concerning Payment or Refund of Medical Device User Fees Under MDUFMA," details key considerations and advises preferred methods for pursuing various types of user fee appeals. The guidance notes that "in most instances, FDA believes disputes...are best resolved through a request for internal review through the supervisory chain" rather than more formal actions such as a citizen's petition or public hearing...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.